Market ClarityManagement expects a strong acceleration, underpinned by greater clarity on US tariffs and a buoyant orthopaedics market.
Order BacklogValtecne’s management foresees potential acceleration in sales for the second half, supported by a near all-time high order backlog and anticipated clarity on US tariffs.
Valuation UpsideThe company updated its valuation criteria, leading to a new DCF-based price target of €8.90 per share, representing a 26.2% upside potential to current price levels.